title: Two Epstein-Barr virus-related serologic antibody tests in nasopharyngeal carcinoma screening: results from the initial phase of a cluster randomized controlled trial in Southern China.
abstract: A nasopharyngeal carcinoma (NPC) mass screening trial using a combination of immunoglobulin A antibodies to Epstein-Barr virus capsid antigen and nuclear antigen-1 by enzyme-linked immunosorbent assay in addition to indirect mirror examination in the nasopharynx and/or lymphatic palpation (IMLP) was conducted in southern China. Cantonese aged 30-59 years residing in 2 cities randomly selected by cluster sampling, Sihui and Zhongshan, were invited to participate in this screening from May 2008 through May 2010. Participants were offered fiberoptic endoscopy examination and/or pathologic biopsy if their serologic tests reached our predefined level of high risk or if results from the physical examination indicated possible cancer (i.e., were IMLP positive). A total of 28,688 individuals were voluntarily screened in the initial round. The overall NPC detection rate was 0.14% (41/28,688) with an early diagnosis rate of 68.3% (28/41) during the first year of follow-up. Thirty-eight of 41 cases (92.7%) were detected among the high-risk group, and 7 of 41 cases (17.1%) were detected among the IMLP-positive group. The 2 Epstein-Barr virus serologic tests by enzyme-linked immunosorbent assay could be a feasible alternative for NPC screening in endemic areas. Further follow-up is needed to examine whether screening has an effect on decreasing mortality from NPC in these areas.
authors.affiliation: Department of Epidemiology, Cancer Prevention Center, State Key Laboratory of Oncology, Southern China.
authors.forename: Zhiwei
authors.initials: Z
authors.lastname: Liu
authors.forename: Ming-Fang
authors.initials: MF
authors.lastname: Ji
authors.forename: Qi-Hong
authors.initials: QH
authors.lastname: Huang
authors.forename: Fang
authors.initials: F
authors.lastname: Fang
authors.forename: Qing
authors.initials: Q
authors.lastname: Liu
authors.forename: Wei-Hua
authors.initials: WH
authors.lastname: Jia
authors.forename: Xiang
authors.initials: X
authors.lastname: Guo
authors.forename: Shang-Hang
authors.initials: SH
authors.lastname: Xie
authors.forename: Feng
authors.initials: F
authors.lastname: Chen
authors.forename: Yue
authors.initials: Y
authors.lastname: Liu
authors.forename: Hao-Yuan
authors.initials: HY
authors.lastname: Mo
authors.forename: Wan-Li
authors.initials: WL
authors.lastname: Liu
authors.forename: Yuan-Long
authors.initials: YL
authors.lastname: Yu
authors.forename: Wei-Min
authors.initials: WM
authors.lastname: Cheng
authors.forename: You-Ye
authors.initials: YY
authors.lastname: Yang
authors.forename: Biao-Hua
authors.initials: BH
authors.lastname: Wu
authors.forename: Kuang-Rong
authors.initials: KR
authors.lastname: Wei
authors.forename: Wei
authors.initials: W
authors.lastname: Ling
authors.forename: Xiao
authors.initials: X
authors.lastname: Lin
authors.forename: Er-Hong
authors.initials: EH
authors.lastname: Lin
authors.forename: Weimin
authors.initials: W
authors.lastname: Ye
authors.forename: Ming-Huang
authors.initials: MH
authors.lastname: Hong
authors.forename: Yi-Xin
authors.initials: YX
authors.lastname: Zeng
authors.forename: Su-Mei
authors.initials: SM
authors.lastname: Cao
mesh_terms: D000328:Adult; D000914:Antibodies, Viral; D000956:Antigens, Viral; D036022:Capsid Proteins; D002277:Carcinoma; D002681:China / Q000453:epidemiology; D055088:Early Detection of Cancer / Q000379:methods*; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D000077274:Nasopharyngeal Carcinoma; D009303:Nasopharyngeal Neoplasms / Q000175:diagnosis*
chemical_list: D000914:Antibodies, Viral; D000956:Antigens, Viral; D036022:Capsid Proteins; C041788:Epstein-Barr viral capsid antigen